PolyPeptide Group AG

Swiss Stock Exchange PPGN.SW

PolyPeptide Group AG Shareholders' Equity for the year ending December 31, 2023: USD 420.78 M

PolyPeptide Group AG Shareholders' Equity is USD 420.78 M for the year ending December 31, 2023, a -6.74% change year over year. Shareholders' equity are the residual interest in the assets of a company after deducting liabilities, representing the shareholders' ownership claim.

PolyPeptide Group AG Shareholders' Equity for the year ending December 31, 2022 was USD 451.17 M, a -5.90% change year over year.
PolyPeptide Group AG Shareholders' Equity for the year ending December 31, 2021 was USD 479.44 M, a 120.92% change year over year.
PolyPeptide Group AG Shareholders' Equity for the year ending December 31, 2020 was USD 217.02 M, a 29.43% change year over year.
PolyPeptide Group AG Shareholders' Equity for the year ending December 31, 2019 was USD 167.68 M, a -0.79% change year over year.

Key data

Date	Shareholders' Equity	Minority Interest	Total Equity	Total Stockholders Equity and Liabilities

Swiss Stock Exchange: PPGN.SW

PolyPeptide Group AG

CEO	Mr. Juan Jose Gonzalez
IPO Date	April 28, 2021
Location	Switzerland
Headquarters	Dammstrasse 19
Employees	1,277
Sector	Healthcare
Industries Pharmaceuticals Biotechnology Cosmetics Personal Care Pet Food Petrochemicals Plastics Vaccines

Description

PolyPeptide Group AG operate as a contract development and manufacturing company worldwide. It focuses on proprietary and generic GMP-grade peptides used by pharmaceutical and biotech companies in approved pharmaceutical products, drugs in clinical development, and in generic products. It engages in manufacturing custom research grade peptides; and developing neoantigen peptide to support personalized cancer therapies. The company is also involved in manufacturing peptides for commercially approved peptide therapeutics. In addition, it manufactures peptide-based generics for human and veterinary markets; and cosmetic peptides. Further, the company offers regulatory affair support services. The company was founded in 1952 and is headquartered in Zug, Switzerland. PolyPeptide Group AG is a subsidiary of Draupnir Holding B.V.

Key trends

Past 5 years